The 'necessity' of a fasting lipid panel for assessment of atherosclerotic cardiovascular disease (ASCVD) risk has been assumed now for decades. The rationale for this position has been the estimation of levels of low density lipoprotein cholesterol (LDL-C), a major risk factor for ASCVD, by correcting for non-fasting changes in plasma triglycerides using the so-called and triglycerides (TG), and then subtracting from the total cholesterol concentration the HDL-C plus very low density lipoprotein cholesterol (VLDL-C) which is estimated by TG/5. This formula is not used when plasma TG >400 mg/dL because in this metabolic setting VLDL particles contain relatively less cholesterol and VLDL-C contribution is therefore overestimated and the calculated LDL-C is falsely low.
The scientific rationale for addressing the importance of fasting vs. non-fasting is that food consumption results in variable increases in plasma TG. Here the effect is not only that of dietary fat but also carbohydrate. Carbohydrate intake increases VLDL TG secretion within 30-90 minutes after ingestion whereas fat intake in normotriglyceridemic people increases plasma TG via chylomicron assembly and secretion from the small intestine over an interval up to 8
hours. Moreover, even without eating fasting triglycerides are subject to substantial biological variability, e.g. up to 30% 4 .
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This 'necessity' of fasting to estimate LDL-C risk for all cause mortality and CVD mortality has now been challenged by Doran et al in this issue of Circulation 5 . Their report provides convincing evidence over a long interval of 14 years in middle-aged USA men and women that non-fasting vs. fasting LDL-C values provide equal predictability for all cause mortality and CVD mortality (ASCVD + congestive heart failure). Of course congestive heart failure (CHF) has other etiologies than coronary heart disease and it would have been instructive if analyses excluding subjects with CHF would have been included in the manuscript. To accomplish this the authors used propensity score matching to accrue fasting and non-fasting cohorts of 4299 individuals each with similar baseline characteristics from 20,024 NHANES-III (1988) (1989) (1990) (1991) (1992) (1993) (1994) participants. Important to note is that these were two different populations, a necessary limitation in this type of epidemiological inquiry. In these cohorts smoking was identified in >50% of both groups reflecting the historic nature of these data, and in part the relatively high number of deaths.
The definition of fasting vs. non-fasting placed at 8 hours was somewhat arbitrary, but defended by the authors as a definition used in previous analyses. For patients with normal fasting triglycerides, i.e. <150 mg/dL, this may be acceptable but is less so in patients with fasting hypertriglyceridemia. Although subjects included in these cohorts had fasting TG <400 mg/dL, wherein fasting chylomicronemia should be absent, in patients with moderate fasting hypertriglyceridemia, e.g. 150-400 mg/dL, postprandial TG excursion may not return to pre-meal levels by up to 12 hours 6, 7 . This concern, however, was in part addressed by also examining the impact of the calculated LDL-C on all cause mortality and CVD mortality by variable intervals of fasting, i.e. from <4 vs. > 4 hours and <12 vs. >12 hours, and finding similar predictability. In addition, even in the unmatched cohort the C-statistics of TG levels in fasting vs. non-fasting 1988-1994) participants. Important to note is that these were two different pop pu ul ulat at tio ions ns n , , , a a a necessary limitation in this type of epidemiological inquiry. In these cohorts smoking was d den en nti ti tifi fi fied ed ed i i in n n > > >50% 0% % o of both groups reflecting the e h h his storic nature of f f t these se e d d data, and in part the e ela a ati tively high h n nu umb mb mbe er r o o of f f de de deat at ath hs hs.
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At this time the practicality of non-fasting favors this approach and it may be time to make a change. However, in anticipation of more frequent updates of the 2013 ACC/AHA Cholesterol Guideline, perhaps new evidence will accumulate to consider that an 8 or 12 hour fast is no longer needed to assess the relationship between plasma lipids and all cause and/or CVD mortality, but also ASCVD risk. Until then, let the 12 hour fast recommendation remain.
